2017_SBRT_Course Book

Proof of principle: Golden Lancet Oncol 2015 Response Survival

Improved OS in responders

Abscopal response: 11/41 (26.8%)

Ø ¼ of the patients with abscopal effect Ø Improved OS in patients with abscopal effect

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

33

/

Prior RT

42 (43%)

OS

PFS

Shaverdian Lancet Oncol 2017

• Palliative RT in 61%; SRT in only 25% Ø Tx-related pulmonary toxicity: (n=3) vs (n=1)

07.09.17 ESTRO SBRT COURSE 2017 - Matthias Guckenberger

34

/